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MicroenvironmentTreatment failure through radioresistance of tumours is associated with activation of the epidermal
growth factor receptor (EGFR). Tumour cell proliferation, DNA-repair, hypoxia and metastases-formation
are four mechanisms in which EGFR signalling has an important role. In clinical trials, a correlation has
been demonstrated between high EGFR expression in tumours and poor outcome after radiotherapy.
Inhibition of EGFR signalling pathways improves the effectiveness of radiotherapy of head and neck can-
cers by overcoming these main mechanisms of radioresistance. The fact that only a minority of the
patients respond to EGFR inhibitors reﬂects the complexity of interactions between EGFR-dependent sig-
nalling pathways and the tumour microenvironment. Furthermore, many components of the microenvi-
ronment are potential targets for therapeutic interventions. Characterisation of the interaction of EGFR
signalling and the tumour microenvironment is therefore necessary to improve the effectiveness of com-
bined modality treatment with radiotherapy and targeted agents. Here, the current status of knowledge
is reviewed and directions for future research are discussed.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 17–23The epidermal growth factor receptor (EGFR) attenuates the
efﬁcacy of radiotherapy in tumour cell killing through its associa-
tion with enhanced proliferation, DNA-repair and hypoxia. Intra-
cellular signalling of EGFR occurs via phosphorylation cascades in
different pathways in which protein kinase B (PKB/AKT) is a key-
regulating factor. However, immunohistochemical staining of EGFR
and phosphorylated (p)AKT shows that EGFR-independent activa-
tion of AKT also occurs, predominantly in hypoxic areas [1,2]. This
observation suggests that activation of speciﬁc proteins in the
important signalling cascades may also depend on microenviron-
mental characteristics, such as tumour oxygenation status. Vice
versa, manipulation of EGFR affects the tumour cells [1]. Under-
standing the microenvironmental conditions that inﬂuence impor-
tant signalling pathways in tumours insensitive to particular
treatment regimens can improve the selection of patients for indi-
vidualised treatment options. In this review we will discuss the
interactions between the EGFR signalling cascade and the tumour
microenvironment (Fig. 1), using mainly preclinical data as well
as the available, albeit limited information from clinical studies.Tumour microenvironment
Our current conception of a malignant tumour is that of a
complex structure containing not only cancer cells but also a vari-
ety of normal cell types that intimately interact with a microen-
vironment that is characterised by both temporal and spatial
heterogeneity. It has become clear that this tumour microenvi-
ronment is important during early cancer development and pro-
gression, and is also of inﬂuence on the response of tumours to
radiation [3,4]. Elements that make up the tumour microenviron-
ment include endothelial cells of the blood and lymphatic vessels,
ﬁbroblasts, inﬁltrating cells of the immune system and the tu-
mour extracellular matrix (ECM) [5]. Availability of oxygen and
nutrients depends on the functionality of the vascular bed and af-
fects the metabolic state of tumour and stromal cells. An imbal-
ance between oxygen and glucose supply and consumption will
result in hypoxia and acidiﬁcation. Within the tumour microenvi-
ronment, hypoxia is relevant in almost all solid tumours. Reduced
oxygen supply can be lethal for some cells, but others are able to
survive under even severe or prolonged hypoxic conditions. Hy-
poxia-induced cell signalling promotes tumour growth, migration
and survival. The development of new vasculature within a tu-
mour involves the formation of new vessels from endothelial cells
(vasculogenesis) in addition to sprouting (angiogenesis) of new
vessels from existing ones [6]. New tumour blood vessels, prere-
quisite for tumour progression and metastasis formation, the
result of interplay between pro- and anti-angiogenic factors, is
Fig. 1. Interaction between EGFR signalling, radiotherapy and the tumour micro-
environment leading to radioresistance. Different aspects of the tumour microen-
vironment can activate signalling pathways, via EGFR or directly and EGFR-
independent. Activation of downstream proteins/genes affects the tumour micro-
environment, e.g. via angiogenic factors and effects on the extracellular matrix.
Both tumour microenvironmental factors as well as EGFR signalling can lead to
more radioresistant tumours.
18 Interaction EGFR and tumour microenvironmentpredominantly regulated through transcription of the hypoxia-
inducible-factor (HIF)-1 complex. The pro-angiogenic factor VEGF
is a crucial gene involved in angiogenesis that is strongly induced
by hypoxia. Anti-angiogenic therapy, for example by using anti-
VEGF monoclonal antibodies such as bevacizumab, can result in
a reduction of tumour vascularisation, but counter-intuitively also
in normalisation of the aberrant tumour vasculature, thereby
improving oxygenation and blood ﬂow that could enhance the
efﬁcacy of radiation [7,8]. However, VEGF can also be upregulated
in an oxygen-independent manner. Also, low extracellular pH
causes stress-induced alteration of gene expression including
the upregulation of VEGF in tumour cells in vitro. Tissue pH ap-
pears to regulate VEGF transcription through a different pathway
independently of hypoxia, namely Ras-ERK1/2 instead of HIF
mediated [8].
Cancer-associated ﬁbroblasts can inﬂuence different aspects of
tumour cell behaviour such as growth and migration trough re-
lease of growth factors and chemokines. Various cells of the im-
mune system found in solid tumours play an important role in
modulating tumour growth. Macrophages form a major inﬂamma-
tory population in most cancers but other components of the
inﬂammatory inﬁltrate also module tumour behaviour, having
pro- and anti-tumour functions [5].
Exchange of information between tumour cells can occur from
the ECM to tumour cells directly, via mechanical forces, or can be
mediated by ECM-associated growth factors [9]. The signals trig-
gered by components of the ECM are not function-speciﬁc and
depending on the local environment they can induce proliferation
as well as the phenomenon known as epithelial-mesenchymal
transition (EMT). During this process tumour cells change from
an epithelial morphology to a migratory and invasive, mesenchy-
mal phenotype [10]. Growth factors, such as EGF, and stress stimuli
like hypoxia, have been shown to induce EMT in vitro by inducing
the phosphorylation of E-cadherin resulting in its degradation
thereby linking growth factor receptor signalling to the induction
of EMT [11].Epidermal growth factor receptor and downstream signalling
pathways
EGFR is a transmembrane protein with intrinsic tyrosine kinase
activity that is overexpressed in most epithelial cancers, e.g. in over
80% of head and neck squamous cell carcinomas (HNSCC) [12,13].
Overexpression could lead to resistance of tumour cells against
radiation as demonstrated by in vivo studies [14–16] and is associ-
ated with poor prognosis in HNSCC [13]. (p)EGFR and HER2 expres-
sion are mostly determined by intrinsic features of the tumour cell,
while the activation of downstream kinases is highly inﬂuenced by
the tumour microenvironment [17]. Ligand binding to EGFR in-
duces conformational changes leading to receptor homo- or hete-
rodimerisation at the plasma membrane with one of its family
members, ErbB2 (HER2), ErbB3 or ErbB4. This causes autophospho-
rylation, subsequent receptor internalisation and stimulation of
multiple signalling pathways including ras-mitogen-activated pro-
tein kinase (MAPK)-extracellular signal-regulated kinase (ERK),
phosphatidylinositol-3-kinase-AKT (PI3-K/AKT)), signal transduc-
ers and activators of transcription (STAT) and the phospholipase
C gamma (PLC-) pathways [3,18,19]. These pathways all share that
they counteract radiation efﬁcacy being involved in proliferation,
migration, apoptosis and angiogenesis. Of note is that, besides
through ligand binding, EGFR can also be activated by ionising
radiation itself, again leading to radioresistance [18,20–22]. EGFR
tyrosine kinase inhibition with erlotinib or geﬁtinib improves pro-
gression-free survival in advanced non-small cell lung cancer
(NSCLC) with EGFR mutations [23]. In preclinical studies EGFR-
expression was needed for C225-response, but this was not sufﬁ-
cient to predict response to C225 plus radiotherapy. Evaluation of
the microenvironment revealed that basal expression of additional
growth factor receptors and effects on proliferation, correlated to a
certain extent with response to combined C225-radiotherapy [24].
Combining radiotherapy with the blockage of EGFR by the chimeric
(mouse/human) monoclonal antibody cetuximab, has resulted in
improved locoregional control and survival for patients with
HNSCC [25] demonstrating that EGFR is an clinically relevant target
for molecular therapies in addition to radiation.
A key protein activated through EGFR is AKT that can be phos-
phorylated at Thr308 and Ser473 at the cell membrane after acti-
vation of PI3-K. pAKT then translocates to the cytoplasm and
nucleus where it can activate or deactivate a myriad of substrates
via its kinase activity or via the transcription of genes responsible
for tumour progression. Although most studies correlate high pAKT
expression to poor local control [26,27], there are also studies link-
ing high pAKT to better survival or reduced migration [2,28]. This
suggests that the concept of EGFR induced AKT activation leading
to treatment resistance and poor outcome is a simpliﬁcation of a
complex interaction between the EGFR signalling network and
the tumour microenvironment. Importantly, it is shown that hy-
poxia can induce cellular changes and in hypoxic areas of HNSCC
activated AKT has been observed in the absence of EGFR expression
(Fig. 2). Immunohistochemical staining for EGFR and pAKT in biop-
sies of patients with HNSCC reveals a lack of association: tumour
cells positive for EGFR were found negative for pAKT and vice-ver-
sa (Fig. 3). Although a better correlation between activated EGFR
(pEGFR) and pAKT existed, there were still tumour cells present
with pAKT but no pEGFR [2]. A possible explanation is that AKT
can be activated by different members of the ErbB family and other
type of receptors like VEGFR. This is supported by the observation
that blocking VEGFR-2 caused a suppression of pAKT [29]. Also,
these observations suggest that the tumour microenvironment
may stimulate the activation of AKT in an EGFR-independent man-
ner and is likely to be involved in the other EGFR-driven signalling
pathways as well.
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Not only do tumours from different origins respond differently
to radiotherapy, also tumours with similar pathology show broad
variations in response. Resistance of cancer cells to radiation is
complex and many intrinsic and extrinsic factors are involved.
Activation of EGFR signalling pathways can inﬂuence various cellu-
lar functions that are involved in the major mechanisms leading to
radioresistance including tumour cell proliferation, DNA-repair
and hypoxia. Activation of EGFR is also involved in a fourth mech-
anism leading to radioresistance of tumours namely the escape of
tumour cells from local therapy by radiation through the formation
of metastases.Tumour cell proliferation
The accelerated proliferation rate of tumour cells during radio-
therapy is one reason for locoregional failure [30]. A number of
clinical trials have conﬁrmed that shortening the overall treatment
time leads to increased tumour control probability by reducing the
possibility of tumour cells to enhance repopulation between radio-
therapy fractions [31]. This accelerated proliferation rate can be a
result of activation of EGFR in response to ionising radiation and
an explanation why tumours with high EGFR expression have a
worse prognosis [13]. Two clinical studies have indeed conﬁrmed
that accelerated radiotherapy, either moderate acceleration with
6 fractions per week over 5.5 weeks or accelerated hyperfractiona-
tion with 3 fractions a day, and a total treatment time of 12 consec-
utive days, results in better locoregional control when EGFR was
overexpressed, but not in tumours with low EGFR expression
[30,32]. This suggests that EGFR-related signalling is involved in
the proliferative response to radiotherapy thereby enhancing tu-
mour survival probabilities. Preclinical data conﬁrm that radia-
tion-induced activation of EGFR represents a critical step in the
activation of this mechanism [33]. Large-scale studies with frac-
tionated irradiation in xenografted FaDu (HNSCC) tumours demon-
strated that after 3–4 weeks of fractionated radiotherapy an
enhancement of repopulation occurs. At the same time an upregu-
lation of EGFR expression was observed, indicating that EGFR is in-
volved in this response [34]. Inhibition of EGFR through cetuximab
[35] or tyrosine-kinase inhibitors such as erlotinib [15] was foundFig. 2. Immunohistochemial staining of whole consecutive laryngeal tumour sections sho
with pimonidazole (green; A). Red is EGFR expression, mostly seen in normoxic areas closto reduce tumour cell repopulation. EGFR inhibition with cetux-
imab during fractionated radiotherapy reduced tumour cell repop-
ulation and improved local control in FaDu tumours [35] but also
leads to a change in the spatial distribution of EGFR favouring
the membranous expression [36]. Erlotinib can inhibit radiation-
induced activation of EGFR thereby reducing its proliferative sig-
nalling capacity. Both agents have been demonstrated to lower
the percentage of human tumour cells in the more radioresistant
S-phase fraction and induce an accumulation of cells in the more
radiosensitive cell cycle phases [37]. Consistent with these ﬁnd-
ings, Krause et al. observed a signiﬁcantly lower S-phase fraction
measured by BrdU labelling after treatment with a tyrosine kinase
inhibitor in FaDu tumours compared to the untreated tumour.
However, this reduced proliferation did not lead to improved local
tumour control after radiation [38]. Additionally, Gurtner et al.
showed that in a panel of HNSCC models erlotinib as well as cetux-
imab lead to tumour growth delay but only simultaneous applica-
tion of cetuximab during fractionated irradiation improved local
control, while erlotinib did not enhance the radiotherapy effect
[39], illustrating that different models of EGFR inhibition may lead
to different ultimate treatment results.DNA-repair
Activation of the EGFR downstream pathways RAS and PI3-K/
AKT have been found to increase the resistance of tumour cells
to agents that cause DNA damage [40]. DNA double stranded
breaks (DSB) are the most important DNA lesions leading to cell kill
after radiotherapy. Tumour cells can repair DSBs through non-
homologous end-joining (NHEJ) and homologous recombination
(HR). NHEJ is the major process responsible for survival of cells ex-
posed to ionising radiation, making this type of repair probably
most inﬂuencial for treatment outcome. An important molecular
complex involved in this process is the DNA-dependent protein ki-
nase catalytic subunit (DNA-PKcs), which is known to reside pri-
marily in the nucleus. An interaction between nuclear EGFR and
DNA-PKcs has been described suggesting a crucial role of nuclear
EGFR for regulation of DNA repair after radiation [41]. Activated
EGFR can be internalised and translocated to the nucleus and irra-
diation-induced nuclear EGFR can stimulate the formation of the
nuclear EGFR/DNA-PKcs complex [42]. Selective inhibition of thesews that pAKT (green) expression (B) occurs predominantly in hypoxic areas stained
er to tumour blood vessels (white). 200magniﬁcation. Scale bars represent 100 m.
Fig. 3. Mismatch of EGFR (red) and pAKT (green) in tumour sections of a laryngeal carcinoma (200 magniﬁcation). A tumour section with EGFR expression is present but
there are no activated AKT (white arrow) and tumour cells with EGFR-independent pAKT expression (yellow arrow). White is tumour vasculature (stained with PAL-E). Scale
bar represents 100 m.
20 Interaction EGFR and tumour microenvironmentpathways was found effective in reducing tumour cell survival. For
example, cetuximab blocked radiation-induced nuclear transloca-
tion of EGFR and was associated with the inhibition of radiation-in-
duced activation of DNA-PKcs in a human bronchial carcinoma cell
line [42]. Combined treatment of radiation and cetuximab resulted
in a redistribution of DNA-PKcs from the nucleus to the cytoplasm.
The reduction of DNA-PKcs in the nucleus leads to impeded NHEJ,
essential for DNA-repair and survival. This might be a potential
mechanism of the combined modality approach whereby the re-
pair of DNA-DSBs after radiotherapy is impaired by cetuximab
[37]. Blockage of radiation-induced DNA-PKcs activation by EGFR,
PI3-K or AKT inhibition as well as through knockdown of AKT1
by siRNA indicates the requirement of the EGFR-PI3-K/AKT path-
way for the regulation of DNA-DSB repair after exposure to ionising
radiation [43]. Selective EGFR inhibition by geﬁtinib increased
radiosensitivity of stem-like gliomaspheres by reducing DNA-PKcs
expression, accompanied by reduced repair of radiation-induced
DNA DSBs [44]. These studies suggest that EGFR mediated repair
of DNA damage might play a prominent role in the mechanism
of radioresistance. Further preclinical in vivo and clinical research
is required to determine to what extent this is a tumour type spe-
ciﬁc mechanism and to identify predictors of response to EGFR- or
downstream PI3-K/AKT-targeted DNA-repair inhibitor.
In conﬂict with other studies, a novel ﬁnding showed that
cetuximab as well as irradiation can promote EGFR translocation
to the nucleus. Cetuximab treatment resulted in phosphorylation
of the EGFRy845 site leading to an increased translocation to the nu-
cleus of HNSCC tumour cells. This process can be inhibited by
dasatinib, an inhibitor of several kinases including SRC family ki-
nases (SFKs), which are suggested to be necessary for the phos-
phorylation of the EGFRy845 site and cetuximab-induced EGFR
translocation to the nucleus [45]. Whether this cetuximab-induced
nuclear EGFR is able to activate target genes to the same extend as
ligand binding or radiation does is still unclear.Hypoxia
The consequences of tumour cell hypoxia for treatment and pa-
tient outcome have been well established [46,47]. Hypoxia is asso-
ciated with treatment failure as hypoxic tumour cells are
signiﬁcantly more resistant to radiation than normoxic cells.
Although hypoxia is considered a limiting factor for tumour
growth it is a stimulus for invasion and metastasis formation [5].
To adapt to hypoxic conditions, cells can respond by activating hy-
poxia-inducible genes or pro-survival signalling pathways, directly
or indirectly through induction of the transcription factor hypoxia-
inducible-factor (HIF)-1 complex [48,49]. HIF-1 modulates the
expression of genes involved in cell survival, angiogenesis and
migration [10,50,51]. After HIF activation by hypoxia, processes
are induced in cells to adapt to low oxygen levels, including meta-
bolic changes and angiogenesis. Various treatment strategies have
been developed to address the hypoxia problem [52,53]. The hyp-
oxic sensitizer nimorazole has been shown to improve locoregional
control in HNSCC when applied in conjunction with radiotherapy
[54]. Also, ARCON (accelerated radiotherapy with carbogen breath-
ing (98% O2, 2% CO2) and nicotinamide) a treatment method that
aims to counteract both tumour cell repopulation and hypoxic
radioresistance has demonstrated beneﬁt for hypoxic laryngeal
carcinomas [55,56]. A meta-analysis demonstrated that in level
1a there is evidence in favour of adding hypoxic modiﬁcation to
radiotherapy in HNSCC [53].
In biopsies of breast cancer patients, expression of HIF-1 is asso-
ciated with EGFR expression [57]. A feedback loop between hypox-
ia-induced upregulation of HIF-1 and EGFR provides sustained
signalling when oxygenation of tumour cells improves, even up
to normoxic conditions. Preclinical research shows that the activa-
tion of HIF is required for the up-regulation of EGFR protein levels
in hypoxic cancer cells. Conversely, EGFR-driven PI3-K/AKT activa-
tion in breast cancer cells can also lead to increased levels of HIF-1
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PI3-K/AKT signalling mediates the induction of HIF is not clear
yet and is not conﬁrmed in other tumour cell lines [59], suggesting
that this phenomenon may be cell type speciﬁc. In cervix carci-
noma and pheochromocytoma cells, hypoxia resulted in the induc-
tion of HIF-1 proteins with AKT activation present. However, after
growth factor stimulation under normoxic conditions there was no
induction of the HIF protein and/or its transcriptional activity
although the treatment resulted in activation of the PI3-K/AKT
pathway. These data suggest that merely the activation of this
pathway may not be sufﬁcient for the accumulation of the HIF-1
protein, at least not in all tumour types.
Thus, interactions between the EGFR-PI3-K/AKT and HIF path-
ways vary with tumour type and oxygenation status. Furthermore,
different effects can be measured at protein and mRNA levels. For
example, blocking EGFR in HNSCC cells leads to decreased transla-
tion of HIF-1 protein under hypoxia, but inhibition does not com-
pletely eliminate HIF expression under hypoxic circumstances
nor are the HIF-1 mRNA levels altered [60]. Pore et al. also found
that nelvavir, a drug known to inhibit PI3-K/AKT signalling, de-
creases HIF-1 protein expression in HNSCC and lung cancer cells
indicating that hypoxia-driven EGFR signalling might act via this
downstream pathway in these tumour types [61]. HIF activation
can also occur via radiation-induced EGFR signalling. Recently, Lu
et al. showed that cetuximab could inhibit radiation-induced
HIF-1 upregulation in HNSCC [62]. This inhibitory effect of cetux-
imab was much weaker for hypoxia-induced HIF-1 than for radia-
tion-induced HIF-1 expression supporting the mediator role of
EGFR in the latter. In addition, a connection between EGFR and
VEGF, a downstream target of HIF-1 exists and EGFR inhibition
using erlotinib leads to downregulation of HIF-1 expression and
decreased VEGF secretion [29]. Erlotinib improves tumour oxygen-
ation via improved vascular perfusion but this decrease in hypoxia
did not seem to have an effect in radiosensitivity in HNSCC xeno-
grafts and cells [63]. Geﬁtinib treatment reduced pimonidazole
binding in A431 xenografts after 5 and 8 days of treatment show-
ing that geﬁtinib reduces intratumoural hypoxia [64].
These data indicate that activation of hypoxia-inducible genes
is cell type speciﬁc, and that there is an intricate interaction be-
tween growth factor receptor activation and microenvironmental
signalling. Tumour cell hypoxia can result in creating an optimal
environment for tumour regrowth by activating hypoxia-induced
genes leading to angiogenesis, while it also is associated with de-
creased radiation-induced DNA damage and a poorer response to
radiotherapy making hypoxia a key element in the clinical out-
come of patients [65]. Therefore, inhibition of EGFR in combination
with hypoxia modiﬁcation should be further explored as it might
offer a powerful strategy for treatment of a number of cancer types.
Experimental evidence has also provided a relationship be-
tween EGFR signalling and angiogenic proteins such as VEGF. Tu-
mours often express high levels of VEGF leading to an abnormal
vasculature. Vascular normalisation and an increase in tumour
blood ﬂow can be achieved by directly targeting VEGF or its recep-
tor (VEGFR), with for example the anti-VEGFR monoclonal anti-
body bevacizumab. Also, EGFR inhibition with erlotinib in mice
bearing SQ20B head and neck xenografts caused changes in vessel
morphology, a decreased vascular permeability and an increase in
tumour blood ﬂow. This indicates that EGFR inhibition has an ef-
fect on vasculature resulting from a decrease in VEGF expression
[63]. The combination of four weeks treatment with cetuximab
and ZD6474, a potent inhibitor of VEGFR-2 tyrosine kinase with a
signiﬁcant anti-EGFR tyrosine kinase activity, showed a more sig-
niﬁcant growth inhibition in mice bearing colon or lung adenocar-
cinoma xenografts as compared to single agent treatment [29]. A
normal tumour vasculature and improvement in tumour bloodﬂow can lead to better drug delivery or increased tumour oxygen-
ation, and, thereby, a better response to radiotherapy.Metastases formation
The escape of tumour cells from the primary tumour to distant
sites and subsequent formation of metastases is a fourth mecha-
nism leading to treatment failure. During EMT, the loss of E-cad-
herin proteins leads to the disruption of stable adherent
junctions. In addition, cells develop a more mesenchymal pheno-
type, e.g. increased expression of mesenchymal proteins like
vimentin, and thereby more able to spread to secondary locations
in the body. Increasing evidence indicates that EGFR signalling
pathways are implicated in the regulation of proteins involved in
EMT. In cervical as well as prostate cancer cells lines, EGF treat-
ment signiﬁcantly decreased the abundance of E-cadherin protein
and upregulated vimentin expression [66,67]. Also, in surgical
biopsies of cervical carcinomas EGFR overexpression was accom-
panied by decreased E-cadherin and increased vimentin expression
seen by immunoﬂuorescent staining [66].
More evidence was provided by studies using EGFR inhibitors.
An HNSCC tumourmodel in which cells dominantly express epithe-
lial markers was found to be very sensitive to cetuximab, whereas
those expressing mesenchymal markers revealed low sensitivity
[68]. Although the exact interaction was not elucidated, this re-
sponse to EGFR inhibition suggests that there is an association be-
tween EGFR pathways and EMT. However, this interaction between
EGFR signalling and EMT seems to be tumour line speciﬁc. Combin-
ing cetuximab with irradiation induced EMT in the cetuximab-sen-
sitive cells while triggering the reverse mesenchymal-epithelial
transition (MET) in the more mesenchymal cell line [68]. The idea
is that cells that have undergone EMT become less dependent on
EGFR signalling for cell proliferation and survival and are thus less
responsive to EGFR inhibitors [69]. This also points towards a pos-
sibility of using EMT-related proteins as predictive markers for sen-
sitivity to cetuximab. This hypothesis needs to be conﬁrmed in
tumours from patients either sensitive or resistant to EGFR inhibi-
tion but it clearly suggests a potential for individualised treatment
approaches employing EGFR-targeting or more aggressive anti-
metastasis treatment based on EMT phenotype.
Conversely, it has been shown that E-cadherin-mediated-cell–
cell adhesion can trigger a ligand-independent activation of EGFR
thereby regulating various signalling pathways such as MAPK
and AKT [70,71]. Reddy et al. showed that the activation of AKT
and MAPK by E-cadherin mediated cell–cell adhesion in ovarian
cancer cells is regulated by EGFR activation. However, no direct
physical interaction between E-cadherin and EGFR could be de-
tected in the cells used, suggesting the existence of intermediate
molecules [71]. In contrast, it was demonstrated that in oral squa-
mous carcinoma cells E-cadherin can physically interact with and
activate EGFR, leading to the activation of MAPK [70]. This interac-
tion leads to EGFR-E-cadherin complex formation at cell–cell junc-
tions and receptor oligomerisation. Although the exact mechanism
is unclear and needs to be veriﬁed, both studies show that E-cad-
herin may not only act as an adhesion molecule but also as an up-
stream regulator that triggers EGFR signalling pathways.
Further, a relation between oxygenation status and EMT also
exists. Hypoxia can down regulate E-cadherin and upregulate mes-
enchymal markers, indicating that hypoxia can contribute to
metastases-formation through the induction of EMT [72]. The mor-
phological transformation induced by hypoxia in breast cancer and
FaDu cells associated with EMT can be reversed after re-oxygena-
tion or by repression of HIF-1 [72,73]. This ﬁnding at least partly
explains the relation between tumour cell hypoxia, migration
and ultimately metastasis formation.
22 Interaction EGFR and tumour microenvironmentConclusions
There is strong evidence, both from preclinical and clinical stud-
ies that there is a positive correlation between the levels of EGFR
found in tumour cells and resistance to radiation therapy and con-
sequently treatment failure. EGFR signalling pathways are impli-
cated in all major mechanisms of radioresistance. The tumour
microenvironment has important inﬂuences on EGFR signalling.
The fact that only a minority of the patients respond to EGFR inhib-
itors reﬂects the complexity of interactions between the EGFR-
dependent signalling pathways and the tumour microenviron-
ment. To improve the effectiveness of combined modality treat-
ment with radiotherapy and targeted agents two strategies
should be explored. One is patient selection based, not only on
EGFR expression patterns, but also on microenvironmental charac-
teristics to identify the tumour phenotypes that are most likely to
beneﬁt from the combined approach. Second is to combine radio-
therapy, not only with EGFR signalling inhibition but also with
treatments that counteract microenvironmental resistance mecha-
nisms such as hypoxia, e.g. nimorazole, ARCON or angiogenesis
inhibition (VEGF inhibitors). Future preclinical and clinical studies
should focus on these multimodality approaches with mechanistic
basis to bring cancer research forward.Acknowledgement
Financial support by Dutch Cancer Society (KUN 2008-4088 &
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